S
Sridevi Mony
Researcher at Wistar Institute
Publications - 10
Citations - 1255
Sridevi Mony is an academic researcher from Wistar Institute. The author has contributed to research in topics: Immune system & Tumor microenvironment. The author has an hindex of 8, co-authored 10 publications receiving 953 citations. Previous affiliations of Sridevi Mony include Alfred I. duPont Hospital for Children & Manipal University.
Papers
More filters
Journal ArticleDOI
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Thomas Condamine,George A. Dominguez,Je-In Youn,Andrew V. Kossenkov,Sridevi Mony,Kevin Alicea-Torres,Evgenii N. Tcyganov,Ayumi Hashimoto,Yulia Nefedova,Cindy Lin,Simona Partlova,Alfred L. Garfall,Dan T. Vogl,Xiaowei Xu,Stella C. Knight,George Malietzis,Gui Han Lee,Evgeniy Eruslanov,Steven M. Albelda,Xianwei Wang,Jawahar L. Mehta,Meenakshi Bewtra,Anil K. Rustgi,Neil Hockstein,Robert L Witt,Gregory A. Masters,Brian Nam,Denis Smirnov,Manuel A. Sepulveda,Dmitry I. Gabrilovich +29 more
TL;DR: A specific marker of human PMN-MDSC associated with ER stress and lipid metabolism is identified, which provides new insights into the biology and potential therapeutic targeting of these cells.
Journal ArticleDOI
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
Vinit Kumar,Pingyan Cheng,Thomas Condamine,Sridevi Mony,Lucia R. Languino,Judith C. McCaffrey,Neil G. Hockstein,Michael J. Guarino,Gregory A. Masters,Emily Penman,Fred Denstman,Xiaowei Xu,Dario C. Altieri,Hong Du,Cong Yan,Dmitry I. Gabrilovich +15 more
TL;DR: iteration of TAMs in tumor site from monocytic precursors was controlled by downregulation of the activity of the transcription factor STAT3, which has a unique function in the tumor environment in controlling the differentiation of MDSC into TAM.
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
Vinit Kumar,Pingyan Cheng,Thomas Condamine,Sridevi Mony,Lucia R. Languino,Judith C. McCaffrey,Neil G. Hockstein,Michael J. Guarino,Gregory A. Masters,Emily Penman,Fred Denstman,Xiaowei Xu,Dario C. Altieri,Hong Du,Cong Yan,Dmitry I. Gabrilovich +15 more
TL;DR: In this article, the authors demonstrated that the differentiation of TAMs in tumor site from monocytic precursors was controlled by downregulation of the activity of the transcription factor STAT3.
Journal ArticleDOI
Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody
George A. Dominguez,Thomas Condamine,Sridevi Mony,Ayumi Hashimoto,Fang Wang,Qin Liu,Andres Forero,Johanna C. Bendell,Robert L Witt,Neil Hockstein,Prasanna Kumar,Dmitry I. Gabrilovich +11 more
TL;DR: Targeting TRAIL-R2 resulted in elimination of different populations of MDSCs without affecting mature myeloid or lymphoid cells, and these data support the use of this antibody in combination immmunotherapy of cancer.
Journal ArticleDOI
Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population.
Saadi Abdul Vahab,Supratim Sen,Nivedita Ravindran,Sridevi Mony,Anila Mathew,Neetha N Vijayan,Geetha Nayak,Nalini Bhaskaranand,Moinak Banerjee,Kapaettu Satyamoorthy +9 more
TL;DR: Results indicate that there was no statistically significant difference between allele and genotype frequencies of refractory and drug responsive epilepsy patients, and the predicted haplotypes frequencies of the three polymorphisms did not showsignificant difference between cases and controls.